SiSaf has a fantastic opportunity to develop and commercialise its Bio-Courier technology for a range of therapies, but particularly its potential in gene therapy. As an experienced finance professional, it is great to be able to work with Suzanne and the team to realise that value growth.
Distinguished Professor of Medicine and Medical and Molecular Genetics and is the director of the division of Endocrinology and Metabolism. Indianan University School of Medicine
Frost Professor of Ophthalmology and Chairman of the Academic Department of Ophthalmology at St. Thomas’ Hospital
I led the Series A investment in SiSaf not just because of their innovative platform technology, but also the passion of the people behind it.